182 related articles for article (PubMed ID: 37369502)
1. Safety and Efficacy of Trifluridine/Tipiracil Administered After Anti-PD-1 Therapies for Advanced Gastric Cancer.
Nakamura H; Kawazoe A; Okunaka M; Demachi K; Kotani D; Shitara K
In Vivo; 2023; 37(4):1729-1734. PubMed ID: 37369502
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
[TBL] [Abstract][Full Text] [Related]
3. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
4. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
[TBL] [Abstract][Full Text] [Related]
6. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
7. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K
BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568
[TBL] [Abstract][Full Text] [Related]
10. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A
Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903
[TBL] [Abstract][Full Text] [Related]
14. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
16. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
[TBL] [Abstract][Full Text] [Related]
18. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]